MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET, DCE-MRI and molecular biomarkers for early prediction of nonprogression in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab

Autor:	Walburga Engel-Riedel, Deniz Kahraman, Thomas Zander, Matthias Scheffler, Christian Mattonet, Martin L. Sos, Lukas C. Heukamp, Ronald Boellaard, Masyar Gardizi, Karin Toepelt, Adriaan A. Lammertsma, Thorsten Persigehl, Reinhard Büttner, Katharina Koenig, Carsten Kobe, Marc Bos, Lucia Nogova, Bernd Neumaier, Juergen Wolf
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty Pathology Bevacizumab business.industry medicine.disease respiratory tract diseases Pharmacokinetics Pharmacodynamics Internal medicine medicine In patient Non small cell Erlotinib Molecular imaging Lung cancer business medicine.drug
Zdroj:	Journal of Clinical Oncology. 32:e19049-e19049
ISSN:	1527-7755 0732-183X
Popis:	e19049^ Background: Molecular imaging tools gain in importance for assessment of pharmacodynamics, pharmacokinetics, prognosis and prediction of therapeutic outcome in patients with advanced NSCLC ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2db608294fdb70d4a382aa8bf6f21f89 https://doi.org/10.1200/jco.2014.32.15_suppl.e19049 Zobrazit plný text záznamu